0 10

Cited 0 times in

Patterns and Outcomes in Hepatocellular Carcinoma Patients with Portal Vein Invasion: A Multicenter Prospective Cohort Study

 Dong Hyun Sinn  ;  Hye Won Lee  ;  Yong-Han Paik  ;  Do Young Kim  ;  Yoon Jun Kim  ;  Kang Mo Kim  ;  Si Hyun Bae  ;  Ji Hoon Kim  ;  Yeon Seok Seo  ;  Jae Young Jang  ;  Byoung Kuk Jang  ;  Hyung Joon Yim  ;  Hyung Joon Kim  ;  Byung Seok Lee  ;  Bo Hyun Kim  ;  In Hee Kim  ;  Eun-Young Cho  ;  Jung Il Lee  ;  Kyung-Suk Suh 
 DIGESTIVE DISEASES AND SCIENCES, Vol.66(1) : 315-324, 2021-01 
Journal Title
Issue Date
Cohort ; Hepatocellular carcinoma ; Portal vein invasion
Background and aims: Sorafenib is a proven first-line treatment recommended for hepatocellular carcinoma (HCC) patients with portal vein invasion (PVI). However, multiple treatment modalities are used in clinical practice as a first-line option. This study is a prospective, observational, multicenter, cohort study evaluating patterns of treatment modalities and outcomes for HCC patients with PVI. Methods: The baseline characteristics, treatment modalities, and outcomes were prospectively collected for 287 newly diagnosed HCC patients with PVI between August 2015 and July 2016 from 16 sites in Korea. Results: During a median 7.8 months of follow-up (range 0.3-24.6 months), mortality was observed in 123 (42.9%) patients. Decision tree analysis classified patients into five subgroups with different outcomes. The patterns of treatment were very heterogeneous, and there was no dominant treatment modality. The most commonly used treatment modality was transarterial chemoembolization (TACE) (20.2%) followed by TACE plus external beam radiation therapy (17.8%) and sorafenib (12.5%). When stratified according to the extent of PVI, sorafenib treatment showed comparable outcomes when the PVI extent was lobal or main/bilateral, yet showed worse outcomes when the PVI extent was limited to the segmental level compared to those who received treatment other than sorafenib. Conclusions: HCC patients with PVI comprise a heterogeneous population and are treated with various treatment modalities with diverse clinical outcomes in clinical practice. Subclassification of HCC patients with PVI is required to minimize heterogeneity and should be considered for the selection of treatment modalities and future clinical trials.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Do Young(김도영)
Lee, Jung Il(이정일) ORCID logo https://orcid.org/0000-0002-0142-1398
Lee, Hye Won(이혜원) ORCID logo https://orcid.org/0000-0002-3552-3560
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.